BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 26658453)

  • 1. Targeting the Wnt/β-catenin pathway in primary ovarian cancer with the porcupine inhibitor WNT974.
    Boone JD; Arend RC; Johnston BE; Cooper SJ; Gilchrist SA; Oelschlager DK; Grizzle WE; McGwin G; Gangrade A; Straughn JM; Buchsbaum DJ
    Lab Invest; 2016 Feb; 96(2):249-59. PubMed ID: 26658453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer.
    Arend RC; Londoño-Joshi AI; Samant RS; Li Y; Conner M; Hidalgo B; Alvarez RD; Landen CN; Straughn JM; Buchsbaum DJ
    Gynecol Oncol; 2014 Jul; 134(1):112-20. PubMed ID: 24736023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. WNT974 Inhibits Proliferation, Induces Apoptosis, and Enhances Chemosensitivity to Doxorubicin in Lymphoma Cells by Inhibiting Wnt/β-Catenin Signaling.
    Chen S; Yuan X; Xu H; Yi M; Liu S; Wen F
    Med Sci Monit; 2020 Jun; 26():e923799. PubMed ID: 32597418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Niclosamide Analogs for Treatment of Ovarian Cancer.
    Walters Haygood CL; Arend RC; Gangrade A; Chettiar S; Regan N; Hassmann CJ; Li PK; Hidalgo B; Straughn JM; Buchsbaum DJ
    Int J Gynecol Cancer; 2015 Oct; 25(8):1377-85. PubMed ID: 26186072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Wnt/β-Catenin Signaling in Neuroendocrine Tumors in vitro: Antitumoral Effects.
    Jin XF; Spoettl G; Maurer J; Nölting S; Auernhammer CJ
    Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32033025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated β-catenin activity contributes to carboplatin resistance in A2780cp ovarian cancer cells.
    Barghout SH; Zepeda N; Xu Z; Steed H; Lee CH; Fu Y
    Biochem Biophys Res Commun; 2015 Dec 4-11; 468(1-2):173-8. PubMed ID: 26522223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance.
    Nagaraj AB; Joseph P; Kovalenko O; Singh S; Armstrong A; Redline R; Resnick K; Zanotti K; Waggoner S; DiFeo A
    Oncotarget; 2015 Sep; 6(27):23720-34. PubMed ID: 26125441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of the Wnt/β-catenin pathway enhances antitumor immunity in ovarian cancer.
    Doo DW; Meza-Perez S; Londoño AI; Goldsberry WN; Katre AA; Boone JD; Moore DJ; Hudson CT; Betella I; McCaw TR; Gangrade A; Bao R; Luke JJ; Yang ES; Birrer MJ; Starenki D; Cooper SJ; Buchsbaum DJ; Norian LA; Randall TD; Arend RC
    Ther Adv Med Oncol; 2020; 12():1758835920913798. PubMed ID: 32313567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling.
    Chau WK; Ip CK; Mak AS; Lai HC; Wong AS
    Oncogene; 2013 May; 32(22):2767-81. PubMed ID: 22797058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting of Wnt/β-Catenin by Anthelmintic Drug Pyrvinium Enhances Sensitivity of Ovarian Cancer Cells to Chemotherapy.
    Zhang C; Zhang Z; Zhang S; Wang W; Hu P
    Med Sci Monit; 2017 Jan; 23():266-275. PubMed ID: 28090074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Manipulating the Wnt/β-catenin signaling pathway to promote anti-tumor immune infiltration into the TME to sensitize ovarian cancer to ICB therapy.
    Wall JA; Meza-Perez S; Scalise CB; Katre A; Londoño AI; Turbitt WJ; Randall T; Norian LA; Arend RC
    Gynecol Oncol; 2021 Jan; 160(1):285-294. PubMed ID: 33168307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delivery of the Porcupine Inhibitor WNT974 in Mice.
    Zhang LS; Lum L
    Methods Mol Biol; 2016; 1481():111-7. PubMed ID: 27590157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Wnt/β-catenin pathway in ovarian cancer: a review.
    Arend RC; Londoño-Joshi AI; Straughn JM; Buchsbaum DJ
    Gynecol Oncol; 2013 Dec; 131(3):772-9. PubMed ID: 24125749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Berbamine suppresses cell proliferation and promotes apoptosis in ovarian cancer partially via the inhibition of Wnt/β-catenin signaling.
    Zhang H; Jiao Y; Shi C; Song X; Chang Y; Ren Y; Shi X
    Acta Biochim Biophys Sin (Shanghai); 2018 Jun; 50(6):532-539. PubMed ID: 29701777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sevoflurane affects neurogenesis through cell cycle arrest via inhibiting wnt/β-catenin signaling pathway in mouse neural stem cells.
    Liu S; Fang F; Song R; Gao X; Jiang M; Cang J
    Life Sci; 2018 Sep; 209():34-42. PubMed ID: 30071197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer.
    Arend RC; Londoño-Joshi AI; Gangrade A; Katre AA; Kurpad C; Li Y; Samant RS; Li PK; Landen CN; Yang ES; Hidalgo B; Alvarez RD; Straughn JM; Forero A; Buchsbaum DJ
    Oncotarget; 2016 Dec; 7(52):86803-86815. PubMed ID: 27888804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. R-spondin 2 promotes osteoblastic differentiation of immature human periodontal ligament cells through the Wnt/β-catenin signaling pathway.
    Arima M; Hasegawa D; Yoshida S; Mitarai H; Tomokiyo A; Hamano S; Sugii H; Wada N; Maeda H
    J Periodontal Res; 2019 Apr; 54(2):143-153. PubMed ID: 30284717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of Wnt/β-Catenin Signaling Is Associated with Downregulation of Wnt1, PORCN, and Rspo2 in Alzheimer's Disease.
    Macyczko JR; Wang N; Zhao J; Ren Y; Lu W; Ikezu TC; Zhao N; Liu CC; Bu G; Li Y
    Mol Neurobiol; 2023 Jan; 60(1):26-35. PubMed ID: 36215026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nerve growth factor modulates the tumor cells migration in ovarian cancer through the WNT/β-catenin pathway.
    Li B; Cai S; Zhao Y; He Q; Yu X; Cheng L; Zhang Y; Hu X; Ke M; Chen S; Zou M
    Oncotarget; 2016 Dec; 7(49):81026-81048. PubMed ID: 27835587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. WNT signaling inducing activity in ascites predicts poor outcome in ovarian cancer.
    Kotrbová A; Ovesná P; Gybel' T; Radaszkiewicz T; Bednaříková M; Hausnerová J; Jandáková E; Minář L; Crha I; Weinberger V; Záveský L; Bryja V; Pospíchalová V
    Theranostics; 2020; 10(2):537-552. PubMed ID: 31903136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.